To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety,
tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA
CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients
with relapsed/refractory multiple myeloma.